

# Joint Working

## Executive Summary

<b>Project title</b>	Halton CCG's Atrial Fibrillation Collaborative Project: Sustainable approach by upskilling primary care workforce
<b>Project partners</b>	Daiichi Sankyo UK Ltd Innovation Agency – Northwest Coast Academic Health Science Network
<b>Start date</b>	March 2022 – March 2023
<b>Project support</b>	Daiichi Sankyo UK Ltd financial contribution £40,189.90 Indirect contribution Innovation Agency – Northwest Coast Academic Health Science Network £51,885

This summary has been written by Daiichi Sankyo with consultation and approval from the Joint Working Group.

### Project summary

The aim of this project is to look at reducing strokes by focusing on improvements to identification and management of Atrial Fibrillation (AF). The project will also focus on reducing variation between practices and patient experience.

1. To reduce inter-practice variation in prevalence of AF (DETECT)
2. To reduce inter-practice variation in anticoagulation of patients with atrial fibrillation at high risk of stroke (PROTECT)
3. To optimize the use of prescription of DOACS in patients with AF (PERFECT)
4. Reducing the prevalence of AF related strokes
5. Encourage the use of technology and innovation to streamline remote support

This will be achieved by increasing clinical confidence and experience in AF management through upskilling primary care workforce of GP's, nurses, advance nurse practitioners and pharmacist and development of pathways and processes. Hence this will support a sustained approach to improve AF management through the development of GP skills and the wider practice team and increase quality of patient experience, through shared decision-making.

Furthermore this project will ensure practices are ready for the forthcoming CVD PREVENT national audit and the national DES for CVD. If the project has positive outcomes then this will be extended across CCGs in Cheshire and Merseyside

## Expected benefits to patients the NHS & Daiichi-Sankyo

### Expected benefits for the Patient:

- Greater opportunity for identification of a significant health condition
- Greater opportunity for optimal treatment
- Greater opportunity for avoiding a life changing stroke and reduction of quality-of-life years
- Stroke risk reduction.
- Evidence based care and prompt treatment regardless of the clinician they see or what practice they are registered with.
- Improve overall patient experience and care.

### Expected benefits for NHS:

- Greater numbers of people who avoid strokes
- Reductions in hospital and ongoing care costs including associated economic and societal benefits
- Reduction in social and health care cost of AF related stroke
- Ensuring practices are ready for the CVD PREVENT national audit and the DES for CVD which starts in Spring 2022.
- Increase in practices QoF points
- Upskill HCP and practice staff to address LTCs
- Reduce inter-practice variation in anticoagulation of patients with atrial fibrillation at high risk of stroke
- Extend this project across CCGs in Cheshire and Merseyside

### Expected benefits for Daiichi Sankyo UK:

- This project will raise the profile of DS
- Improve Daiichi-Sankyo's reputational profile amongst local and national stakeholders and expand its joint working portfolio.
- It is anticipated as part of the project that more patients may be treated with a pharmaceutical product. This may include but is not exclusive to products manufactured by Daiichi Sankyo UK Ltd.
- Journal publication and associated publicity likely resulting in future collaborations and subsequent rise in profile of Daiichi-Sankyo.